FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2332190988> ?p ?o ?g. }

• W2332190988 endingPage "665" @default.
• W2332190988 startingPage "665.2" @default.
• W2332190988 abstract "<h3>Background</h3> Decision-making regarding therapeutic intervention depends on various factors, including knowledge of the risk-benefit profile of each agent. The relative safety of antirheumatic biologic agents is difficult to assess because of the paucity of direct comparative data, relative rarity of adverse events (AEs), and study design and patient population heterogeneity. <h3>Objectives</h3> Review clinical trial and observational study evidence regarding comparative safety of 5 biologics used in the treatment of rheumatoid arthritis (RA), psoriasis, and psoriatic arthritis: adalimumab (ADA), certolizumab pegol (CZP), etanercept (ETN), golimumab (GLM), and infliximab (IFX). <h3>Methods</h3> Search strategy for this systematic safety review utilized: PubMed, Cochrane Databases, Agency for Healthcare Research and Quality (AHRQ), FDA databases and selected studies from bibliographies of retrieved studies. Search terms: DMARD, tumor necrosis factor, the 5 biologics names, FDA-approved conditions, and associated AE types. Studies were evaluated for inclusion based on validity and clinical relevancy. Findings were graded for evidence strength using a modified AHRQ approach: high, moderate, borderline or inconclusive. <h3>Results</h3> In total, 73 publications were included. Numeric differences were observed in the safety profiles of the 5 biologics. Borderline evidence (Table) indicated RA patients treated with ETN compared to those treated with ADA and IFX may have lower risk for serious infections and withdrawal due to AEs. Inconclusive evidence suggested RA patients treated with ADA, ETN, GLM, and IFX may have lower risk for serious infections (SIs) than those receiving CZP. Across studied populations, borderline evidence indicated lower risk with ETN for tuberculosis (TB) than with ADA or IFX, and inconclusive evidence indicated that ETN had a lower risk for opportunistic infections (OIs) and lymphoma than ADA or IFX. <h3>Conclusions</h3> Although the evidence was rated as borderline or inconclusive using a modified AHRQ approach, our systematic review found patterns suggesting differences among ETN, ADA, and IFX in some safety outcomes. These findings add to the existing body of literature to inform managed care formulary decisions. <i>This study was sponsored by Immunex, a wholly owned subsidiary of Amgen Inc. and by Wyeth, which was acquired by Pfizer Inc. in October 2009.</i> <h3>Disclosure of Interest</h3> M. Stuart Consultant for: Amgen Inc, S. Shrite Consultant for: Amgen Inc, S. Gandra Employee of: Amgen Inc" @default.
• W2332190988 created "2016-06-24" @default.
• W2332190988 creator A5002839249 @default.
• W2332190988 creator A5045712307 @default.
• W2332190988 creator A5060749406 @default.
• W2332190988 date "2013-06-01" @default.
• W2332190988 modified "2023-09-26" @default.
• W2332190988 title "AB0478 Systematic safety review of five biologic antirheumatic drugs:" @default.
• W2332190988 doi "https://doi.org/10.1136/annrheumdis-2012-eular.478" @default.
• W2332190988 hasPublicationYear "2013" @default.
• W2332190988 type Work @default.
• W2332190988 sameAs 2332190988 @default.
• W2332190988 citedByCount "0" @default.
• W2332190988 crossrefType "journal-article" @default.
• W2332190988 hasAuthorship W2332190988A5002839249 @default.
• W2332190988 hasAuthorship W2332190988A5045712307 @default.
• W2332190988 hasAuthorship W2332190988A5060749406 @default.
• W2332190988 hasConcept C126322002 @default.
• W2332190988 hasConcept C177713679 @default.
• W2332190988 hasConcept C197934379 @default.
• W2332190988 hasConcept C23131810 @default.
• W2332190988 hasConcept C2776215756 @default.
• W2332190988 hasConcept C2776260265 @default.
• W2332190988 hasConcept C2777138892 @default.
• W2332190988 hasConcept C2777226972 @default.
• W2332190988 hasConcept C2777575956 @default.
• W2332190988 hasConcept C2779134260 @default.
• W2332190988 hasConcept C2780132546 @default.
• W2332190988 hasConcept C2781290027 @default.
• W2332190988 hasConcept C71924100 @default.
• W2332190988 hasConceptScore W2332190988C126322002 @default.
• W2332190988 hasConceptScore W2332190988C177713679 @default.
• W2332190988 hasConceptScore W2332190988C197934379 @default.
• W2332190988 hasConceptScore W2332190988C23131810 @default.
• W2332190988 hasConceptScore W2332190988C2776215756 @default.
• W2332190988 hasConceptScore W2332190988C2776260265 @default.
• W2332190988 hasConceptScore W2332190988C2777138892 @default.
• W2332190988 hasConceptScore W2332190988C2777226972 @default.
• W2332190988 hasConceptScore W2332190988C2777575956 @default.
• W2332190988 hasConceptScore W2332190988C2779134260 @default.
• W2332190988 hasConceptScore W2332190988C2780132546 @default.
• W2332190988 hasConceptScore W2332190988C2781290027 @default.
• W2332190988 hasConceptScore W2332190988C71924100 @default.
• W2332190988 hasIssue "Suppl 3" @default.
• W2332190988 hasLocation W23321909881 @default.
• W2332190988 hasOpenAccess W2332190988 @default.
• W2332190988 hasPrimaryLocation W23321909881 @default.
• W2332190988 hasRelatedWork W1982225076 @default.
• W2332190988 hasRelatedWork W2034184520 @default.
• W2332190988 hasRelatedWork W2057389856 @default.
• W2332190988 hasRelatedWork W2202409929 @default.
• W2332190988 hasRelatedWork W2240357112 @default.
• W2332190988 hasRelatedWork W2293692550 @default.
• W2332190988 hasRelatedWork W2750076135 @default.
• W2332190988 hasRelatedWork W2933506976 @default.
• W2332190988 hasRelatedWork W4213106711 @default.
• W2332190988 hasRelatedWork W4321375011 @default.
• W2332190988 hasVolume "71" @default.
• W2332190988 isParatext "false" @default.
• W2332190988 isRetracted "false" @default.
• W2332190988 magId "2332190988" @default.
• W2332190988 workType "article" @default.